ATE550074T1 - Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril - Google Patents
Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitrilInfo
- Publication number
- ATE550074T1 ATE550074T1 AT05779369T AT05779369T ATE550074T1 AT E550074 T1 ATE550074 T1 AT E550074T1 AT 05779369 T AT05779369 T AT 05779369T AT 05779369 T AT05779369 T AT 05779369T AT E550074 T1 ATE550074 T1 AT E550074T1
- Authority
- AT
- Austria
- Prior art keywords
- amino
- cyanoethenyl
- fumarate
- pyrimidinyl
- dimethylphenyl
- Prior art date
Links
- YDXRTTNWFOUFQF-UHFFFAOYSA-N C(#N)C=CC1=CC(=C(C(=C1)C)C=1C(=C(C(=C(C#N)C1)C1=NC=CC=N1)N)N)C Chemical compound C(#N)C=CC1=CC(=C(C(=C1)C)C=1C(=C(C(=C(C#N)C1)C1=NC=CC=N1)N)N)C YDXRTTNWFOUFQF-UHFFFAOYSA-N 0.000 title 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 title 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title 1
- YIBOMRUWOWDFLG-UHFFFAOYSA-N 4-[[4-[4-(2-cyanoethenyl)-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(C=CC#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-UHFFFAOYSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI20043578A MY169670A (en) | 2003-09-03 | 2004-09-02 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| PCT/EP2004/052028 WO2005021001A1 (en) | 2003-09-03 | 2004-09-03 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| EP05101447 | 2005-02-25 | ||
| PCT/EP2005/054341 WO2006024667A1 (en) | 2004-09-02 | 2005-09-02 | Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE550074T1 true ATE550074T1 (de) | 2012-04-15 |
Family
ID=38091631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05779369T ATE550074T1 (de) | 2004-09-02 | 2005-09-02 | Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20090215804A1 (de) |
| JP (1) | JP4922937B2 (de) |
| AT (1) | ATE550074T1 (de) |
| BR (1) | BRPI0514861A (de) |
| CR (1) | CR9032A (de) |
| DK (1) | DK1789139T3 (de) |
| EA (1) | EA011036B1 (de) |
| ES (1) | ES2384715T3 (de) |
| HR (1) | HRP20120499T1 (de) |
| IL (1) | IL181649A0 (de) |
| MX (1) | MX2007002594A (de) |
| NI (1) | NI200700069A (de) |
| NO (1) | NO339788B1 (de) |
| SI (1) | SI1789139T1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012147091A2 (en) | 2011-04-25 | 2012-11-01 | Hetero Research Foundation | Process for rilpivirine |
| JOP20220086A1 (ar) * | 2019-10-10 | 2023-01-30 | Axcella Health Inc | صياغات منخفضة الحجم تتضمن كيانات حمض أميني |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5498419A (en) * | 1994-06-03 | 1996-03-12 | Pars; Harry G. | Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric |
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| PL208533B1 (pl) * | 2002-08-09 | 2011-05-31 | Janssen Pharmaceutica Nv | Sposób otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu oraz sposób otrzymywania związku pośredniego |
| WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| CL2004000192A1 (es) * | 2003-02-07 | 2005-03-18 | Janssen Pharmaceutica Nv | Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja. |
-
2005
- 2005-09-02 SI SI200531539T patent/SI1789139T1/sl unknown
- 2005-09-02 HR HRP20120499TT patent/HRP20120499T1/hr unknown
- 2005-09-02 AT AT05779369T patent/ATE550074T1/de active
- 2005-09-02 BR BRPI0514861-8A patent/BRPI0514861A/pt not_active Application Discontinuation
- 2005-09-02 US US11/574,452 patent/US20090215804A1/en not_active Abandoned
- 2005-09-02 MX MX2007002594A patent/MX2007002594A/es active IP Right Grant
- 2005-09-02 ES ES05779369T patent/ES2384715T3/es not_active Expired - Lifetime
- 2005-09-02 EA EA200700534A patent/EA011036B1/ru unknown
- 2005-09-02 JP JP2007528885A patent/JP4922937B2/ja not_active Expired - Lifetime
- 2005-09-02 DK DK05779369.7T patent/DK1789139T3/da active
-
2007
- 2007-03-01 IL IL181649A patent/IL181649A0/en active IP Right Grant
- 2007-03-01 NI NI200700069A patent/NI200700069A/es unknown
- 2007-03-30 CR CR9032A patent/CR9032A/es not_active Application Discontinuation
- 2007-04-02 NO NO20071720A patent/NO339788B1/no unknown
-
2011
- 2011-03-04 US US13/040,465 patent/US20110150996A1/en not_active Abandoned
-
2017
- 2017-12-22 US US15/852,181 patent/US20180116964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20071720L (no) | 2007-04-02 |
| EA011036B1 (ru) | 2008-12-30 |
| US20110150996A1 (en) | 2011-06-23 |
| US20180116964A1 (en) | 2018-05-03 |
| IL181649A0 (en) | 2007-07-04 |
| SI1789139T1 (sl) | 2012-08-31 |
| CR9032A (es) | 2009-07-30 |
| NI200700069A (es) | 2015-12-10 |
| NO339788B1 (no) | 2017-01-30 |
| HRP20120499T1 (hr) | 2012-07-31 |
| ES2384715T3 (es) | 2012-07-11 |
| BRPI0514861A (pt) | 2008-06-24 |
| JP2008511591A (ja) | 2008-04-17 |
| JP4922937B2 (ja) | 2012-04-25 |
| HK1112862A1 (en) | 2008-09-19 |
| US20090215804A1 (en) | 2009-08-27 |
| DK1789139T3 (da) | 2012-07-09 |
| MX2007002594A (es) | 2007-04-25 |
| EA200700534A1 (ru) | 2007-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1600061I1 (hu) | 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-2-pirimidinil]amino]benzonitril | |
| JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
| MEP33808A (hr) | Farmaceutske kompozicije koje obuhvataju inhibitor hmg reduktaze | |
| UA91006C2 (ru) | Способ получения аминокротонильных соединений | |
| TW200633716A (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
| JO2515B1 (en) | Gamma-Crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical composition containing it | |
| WO2009007441A3 (en) | Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile | |
| NO20050524L (no) | Fremgangsmater for fremstillingen av 4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino]-2-pyrimidinyl]amino]benzonitril | |
| TW200609001A (en) | Particulate-stabilized injectable pharmaceutical compositions of posaconasole | |
| ATE541573T1 (de) | Pharmazeutische zusammensetzung enthaltend lapatinib | |
| PL1632232T3 (pl) | Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu | |
| NO20071720L (no) | Fumarat av 4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino]-2-pyrimidinyl]amino]benzonitril. | |
| UA92469C2 (en) | Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile | |
| EA200801614A1 (ru) | Фармацевтическая композиция, содержащая монтелукаст | |
| HRP20110563T1 (en) | Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
| SE0103476D0 (sv) | New use | |
| ITMI20020639A1 (it) | Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea | |
| UY27049A1 (es) | Composiciones farmacéuticas |